Pinyol M, Cobo F, Bea S, Jares P, Nayach I, Fernandez P L, Montserrat E, Cardesa A, Campo E
Hematopathology Section, Laboratory of Pathology, Hospital Clinic, University of Barcelona, Barcelona, Spain.
Blood. 1998 Apr 15;91(8):2977-84.
The molecular mechanisms underlying the pathogenesis of aggressive lymphomas and the histological transformation of indolent variants are not well known. To determine the role of p16(INK4a) gene alterations in the pathogenesis of non-Hodgkin's lymphomas (NHLs) and the histological progression of indolent variants, we have analyzed the expression, deletions, and mutations of this gene in a series of 112 NHLs. Hypermethylation of the gene was also examined in a subset of tumors with lack of protein expression but without mutations or deletions of the gene. p16(INK4a) gene alterations were detected in 3 out of 64 (5%) indolent lymphomas but in 16 out of 48 (33%) primary or transformed aggressive variants. In the low-grade tumors, p16(INK4a) alterations were detected in 1 (4%) chronic lymphocytic leukemia (hemizygous missense mutation), 1 (6%) follicular lymphoma (homozygous deletion), and 1 (5%) typical mantle cell lymphoma (homozygous deletion). The two later cases followed an aggressive clinical evolution. In the aggressive tumors, p16(INK4a) gene alterations were observed in 2 (29%) Richter's syndromes (2 homozygous deletions), 3 (33%) transformed follicular lymphomas (1 homozygous deletion and 2 nonsense mutations), 3 (43%) blastoid mantle cell lymphomas (2 homozygous and 1 hemizygous deletions), 5 (28%) de novo large-cell lymphomas (1 homozygous deletion and 4 hypermethylations), 2 lymphoblastic lymphomas (2 homozygous deletions), and 1 of 2 anaplastic large cell lymphomas (hypermethylation). Protein expression was lost in all tumors with p16(INK4a) alterations except in the typical chronic lymphocytic leukemia (CLL) with hemizygous point mutation. Sequential samples of the indolent and transformed phase of three cases showed the presence of p16(INK4a) deletions in the Richter's syndrome but not in the CLL component of two cases, whereas in a follicular lymphoma the deletion was present in both the follicular tumor and in the diffuse large-cell lymphoma. In conclusion, these findings indicate that p16(INK4a) gene alterations are a relatively infrequent phenomenon in NHLs. However, deletions, mutations, and hypermethylation of the gene with loss of protein expression are associated with aggressive tumors and they may also participate in the histological progression of indolent lymphomas.
侵袭性淋巴瘤发病机制及惰性淋巴瘤组织学转化的分子机制尚不清楚。为了确定p16(INK4a)基因改变在非霍奇金淋巴瘤(NHL)发病机制及惰性淋巴瘤组织学进展中的作用,我们分析了112例NHL中该基因的表达、缺失及突变情况。对于一部分缺乏蛋白表达但无基因缺失或突变的肿瘤,还检测了该基因的高甲基化情况。在64例(5%)惰性淋巴瘤中有3例检测到p16(INK4a)基因改变,而在48例(33%)原发性或转化性侵袭性淋巴瘤中有16例检测到该改变。在低度恶性肿瘤中,1例(4%)慢性淋巴细胞白血病(半合子错义突变)、1例(6%)滤泡性淋巴瘤(纯合子缺失)和1例(5%)典型套细胞淋巴瘤(纯合子缺失)检测到p16(INK4a)改变。后两例临床进展为侵袭性。在侵袭性肿瘤中,2例(29%)里氏综合征(2例纯合子缺失)、3例(33%)转化性滤泡性淋巴瘤(1例纯合子缺失和2例无义突变)、3例(43%)母细胞样套细胞淋巴瘤(2例纯合子和1例半合子缺失)、5例(28%)原发性大细胞淋巴瘤(1例纯合子缺失和4例高甲基化)、2例淋巴母细胞淋巴瘤(2例纯合子缺失)以及2例间变性大细胞淋巴瘤中的1例(高甲基化)检测到p16(INK4a)基因改变。除了具有半合子点突变的典型慢性淋巴细胞白血病(CLL)外,所有发生p16(INK4a)改变的肿瘤均出现蛋白表达缺失。3例患者惰性期和转化期的连续样本显示,里氏综合征中存在p16(INK4a)缺失,而2例患者的CLL成分中未出现该缺失;在1例滤泡性淋巴瘤中,滤泡性肿瘤及弥漫性大细胞淋巴瘤中均存在该缺失。总之,这些发现表明p16(INK4a)基因改变在NHL中相对少见。然而,该基因的缺失、突变及高甲基化伴蛋白表达缺失与侵袭性肿瘤相关,且可能也参与了惰性淋巴瘤的组织学进展。